176 related articles for article (PubMed ID: 9610696)
21. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
24. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
[TBL] [Abstract][Full Text] [Related]
25. Clinical studies of irinotecan alone and in combination with cisplatin.
Fukuoka M; Masuda N
Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
27. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
28. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 2000 Aug; 59(2):105-9. PubMed ID: 10971167
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Natale RB; Socinski M; Sandler A; Israel VP; Miller L
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Rowinsky EK; Flood WA; Sartorius SE; Bowling KM; Ettinger DS
Invest New Drugs; 1997; 15(2):129-38. PubMed ID: 9220292
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
[TBL] [Abstract][Full Text] [Related]
35. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 1999; 56(4):301-7. PubMed ID: 10343194
[TBL] [Abstract][Full Text] [Related]
38. Population-based maximum tolerated dose of irinotecan and carboplatin.
Wild CA; Wang SE; Gandara DR; Lara PN; Meyers FJ; Tanaka M; Houston J; Lauder J; Lau DH
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):11-6. PubMed ID: 12886868
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.
Mori K; Hirose T; Machida S; Yokoyama K; Tominaga K
Eur J Cancer; 1997 Mar; 33(3):503-5. PubMed ID: 9155540
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
